Almotriptan (Axert) vs Sumatriptan succinate injection (Imitrex)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Migraine
Shared mechanism: 5-HT1B/1D receptor · full Migraine pipeline
Almotriptan (Axert)
Rights held by Almirall and partners
NCT00257010 · Phase 3 · completed
This was a single-group, open-label study with 447 enrolled participants and no placebo or active comparator, so the reported pain-free headache counts cannot establish how much benefit was caused by almotriptan. The primary endpoint was a clinical migraine outcome, but no between-group comparison or statistical test was possible.
No aligned efficacy figure on record for this race.
Sumatriptan succinate injection (Imitrex)
Marketed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Migraine
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Almotriptan (Axert): registry results are on file for Migraine, but their comparison mappings are not yet available.
Sumatriptan succinate injection (Imitrex): no structured comparison results are available for Migraine.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Almotriptan (Axert)'s landscape · Sumatriptan succinate injection (Imitrex)'s landscape